PARIS – Alnylam Pharmaceuticals Inc. used the International Liver Congress (ILC) as the forum to report solid success in the phase I and I/II open-label extension (OLE) studies of givosiran to treat acute hepatic porphyrias (AHPs), a family of ultra-rare inherited disorders.